BW20030425002021  20030425T132806Z UTC


( BW)(IVAX-CORPORATION)(IVX) IVAX Names Bodor Chief Scientific Officer 

    Business Editors
    UK REGULATORY NEWS

    MIAMI--(BUSINESS WIRE)--April 25, 2003--

IVAX Corporation (AMEX:IVX) (LSE:IVX.L) announced today that Dr.
Nicholas Bodor has been appointed chief scientific officer. Dr. Bodor
will report to Dr. Phillip Frost, chairman and CEO of IVAX, and will
be responsible for drug discovery and preclinical research and
development.

Dr. Bodor joined IVAX in 1999, and has served as senior vice president
- Basic Research & Drug Discovery - IVAX Research; President - IVAX
Research Institute, Inc.; and managing director and CEO - IVAX Drug
Research Institute, IVAX' research center in Budapest, Hungary. Prior
to joining IVAX, Dr. Bodor served as a graduate research professor at
the University of Florida and as the Executive Director of the
University of Florida's Center for Drug Discovery, which he founded in
1986. Dr. Bodor is an elected Fellow of the Academy of Pharmaceutical
Sciences, the American Association of Pharmaceutical Scientists, The
American College of Clinical Pharmacology, and the American
Association for the Advancement of Science and a member of the
Hungarian Academy of Sciences. He has authored over 485 scientific
articles and has been the recipient of over 185 patents. He has won
some twenty scientific awards, including two Honorary Doctor's
degrees, the Volwiler Research Achievement Award, and being named the
1984 Florida Scientist of the Year. He is on the editorial boards of
over a dozen international scientific journals, and has been a
plenary/invited speaker at well over 400 international symposia.

"We are pleased to name Nick our chief scientific officer," said
Phillip Frost, M.D., chairman and CEO of IVAX. "Nick's outstanding
scholarly background and proven track record in conceptualizing and
commercializing new drug molecules are unique. We are confident that
his continued leadership will keep our worldwide drug discovery on the
cutting edge of science."

IVAX Corporation, headquartered in Miami, Florida, discovers,
develops, manufactures, and markets branded and brand equivalent
(generic) pharmaceuticals and veterinary products in the U.S. and
internationally.

Copies of this and other news releases may be obtained free of charge
from IVAX' website at http://www.ivax.com.

   Short Name: IVAX Corporation
   Category Code: MSC
   Sequence Number: 00004295
   Time of Receipt (offset from UTC): 20030425T134234+0100

    --30--PP/mi* mh/uk

    CONTACT: IVAX Corporation, Miami
             Jim Whitlow, 305/575-6043

    KEYWORD: FLORIDA UNITED KINGDOM INTERNATIONAL EUROPE
    INDUSTRY KEYWORD: PHARMACEUTICAL MEDICAL MANAGEMENT CHANGES
    SOURCE: IVAX Corporation

Today's News On The Net - Business Wire's full file on the Internet
                          with Hyperlinks to your home page.
                          URL: http://www.businesswire.com